Liminatus Pharma, Inc.
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Mailing Address 12611 HIDDENCREEK WAY, CERRITOS, CA, 90703
Phone 213-273-5453
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
-$3.55M
Net Income
$24.75M
Total Liabilities
$-0.20
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 20, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | February 18, 2026 | View on SEC |
| S-1 IPO registration statement | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 9, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
| 8-K Current report of material events | November 25, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
Annual Reports
10-K March 31, 2026
- Developing IBA101, a novel antibody cancer treatment designed to spare healthy cells.
- Successfully completed pre-clinical animal safety studies.
Material Events
8-K Legal Issue February 9, 2026
High Impact
- Liminatus Pharma resolved a major legal dispute with Clear Street LLC.
- The company avoided a substantial cash payment of over $8 million by issuing stock.
8-K Financial Distress January 26, 2026
High Impact
- Liminatus has 180 calendar days to regain Nasdaq compliance.
- Potential strategies for compliance include reverse stock split, positive clinical trial results, strategic partnerships, or a successful capital raise.
Related Companies
Companies in the same industry (SIC: 2836)
Kodiak Sciences Inc.
KOD Biological Products, (No Diagnostic Substances)
BioAtla, Inc.
BCAB Biological Products, (No Diagnostic Substances)
BRAINSTORM CELL THERAPEUTICS INC.
BCLI Biological Products, (No Diagnostic Substances)
Alvotech
ALVO Biological Products, (No Diagnostic Substances)
Green Planet Bio Engineering Co. Ltd.
GPLB Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.